Home Smart 100 2017 F2 Chronic Pain Treatment

F2 Chronic Pain Treatment [SMART 100, 2017]

0

This SMART 100 profile and the information it contains is a duplication of content submitted by the applicant during the entry process. As a function of entry, applicants were required to declare that all details are factually correct, do not infringe on another’s intellectual property and are not unlawful, threatening, defamatory, invasive of privacy, obscene, or otherwise objectionable. Some profiles have been edited for reasons of space and clarity.

Learn more about the SMART 100 >>

1. THE BEGINNING

This innovation initially came to life when…

…although the process for this service was developed and tested in 2001 it has not been commercialised before now. Everyone knows someone with chronic pain, and if it’s a family member there can be an intense desire to find a solution. I felt driven to find that solution, and found a way to switch off chronic pain signalling permanently by interrupting it with precision.

2. WHAT & HOW

The purpose of this innovation is to…

…allow most people to walk out of the clinic with little or no pain, and over a short time around 85% of people get permanent relief from pain and can return to work.

It does this by…

…targeting and interrupting the re-consolidation phase of the conditioned response, we can stop the pain signal in its tracks, and permanently.

3. PURPOSE & BENEFITS

This innovation improves on what came before because…

…currently there is no medication, psychological treatment, or physical therapy that helps the majority of chronic pain patients (quality citations available). In Australia we have approximately 3 million people who are not being helped. We can relieve at least 85% of those people from their pain, permanently.

Its various benefits to the customer/end-user include…

…the person gets to quickly and permanently reduce or eliminate their pain, can return to their role at work or in their community, and under the supervision of their doctor can cease their medication.

4. COMPETITIVE LANDSCAPE

In the past, this problem was solved by…

…to date this problem has not been solved, and claimed success rates have been similar only to placebo. This is a completely innovative approach to chronic pain that no-one else is using (as far as we can determine) and is completely outside currently-accepted treatment protocols.

Its predecessors/competitors include…

…former competitors might have included pain specialists, psychologists, psychologists, and physical therapists. These people should now see us as partners rather than as competitors.

5. TARGET MARKET

It is made for…

…there are several target markets but the largest and most accessible is the workers compensation space, specifically claimants who have unresolved chronic pain that is preventing full return to work, or those who are deemed vulnerable to developing long term chronic pain, or long term psychological injury.

The size of this largest segment of our market is a potential $3.5 billion. It is yet to be seen how much of that we can access.

Based on current feedback from our marketing, we’re confident of winning at least 25% of the top 100 Australian employers as referrers.

It is available for sale through…

…major corporates who drive the business for us. They have a vested interest in cutting their massive workers compensation payouts (currently $7.7 billion per annum – it’s biting them). We’re leveraging through their injury management executives.

Our marketing strategy is to…

…connect with top decision makers in injury management in the top 100 Australian companies (by employee number) and so far they’re keen to meet and discuss because they desperately need to get rising costs under control (workers compensation has doubled in the last 11 years, despite actual claim numbers dropping).

FINE PRINT: This SMART 100 profile and the information it contains is a duplication of content submitted by the applicant during the entry process. As a function of entry, applicants were required to declare that all details are factually correct, do not infringe on another’s intellectual property and are not unlawful, threatening, defamatory, invasive of privacy, obscene, or otherwise objectionable. Some profiles have been edited for reasons of space and clarity.

Maven Judge Vote: F2 Chronic Pain Treatment – Smart 100 2017
(Please note – The form below is for judging purposes only and is restricted to the public)